Martha Raschko

发表

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

N. Callander, S. Miyamoto, S. Markovina, 2007 .

Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

KyungMann Kim, N. Callander, S. Miyamoto, 2008, Molecular Cancer Research.